Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Pacira Biosciences Stock Sank Today

TheMotleyFool

0 0

Shares of Pacira BioSciences (NASDAQ: PCRX) were sinking 12.7% as of 3:33 p.m. EDT on Monday. The decline came after the company announced that eVenus Pharmaceutical Laboratories is seeking Food and Drug Administration approval for a generic version of non-opioid pain drug Exparel.

The possibility of generic competition for Exparel presents a key challenge for Pacira. In the second quarter, the drug generated $130.1 million of the company's total $135.6 million in sales. It's not surprising, therefore, that the pharma stock took a big hit today.

Image source: Getty Images.

Source Fool.com

Like: 0

PCRX

Share